/ABP
ABP Stock - Abpro Corporation
Healthcare|BiotechnologyNASDAQ
$5.06+5.64%
+$0.27 (+5.64%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.2
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $5.57
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ABP
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.01 – $5.11
TARGET (TP)$5.82
STOP LOSS$4.66
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.02
52W High$153.90
52W Low$4.54
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2017 |
|---|---|---|---|---|---|
| Revenue | $183,000 | $122,000 | $2.03M | $480,000 | $2.20M |
| Gross Profit | $183,000 | $122,000 | $-7,725,000 | $-8,147,000 | $676,000 |
| Gross Margin | 100.0% | 100.0% | -380.7% | -1697.3% | 30.7% |
| Operating Income | $-9,921,000 | $-11,746,000 | $-16,685,000 | $-14,977,000 | $-12,357,000 |
| Net Income | $-7,232,000 | $-11,706,000 | $-17,215,000 | $-14,735,000 | $-12,357,000 |
| Net Margin | -3951.9% | -9595.1% | -848.4% | -3069.8% | -561.4% |
| EPS | $-23.10 | $-37.50 | $-55.50 | $-47.70 | $-31.50 |
Company Overview
Abpro Holdings, Inc., a biotechnology company, engages in developing antibody therapeutics for patients with immuno-oncology, ophthalmology, and autoimmunity issues. Its platform DiversImmune addresses a bottleneck in the antibody therapeutics industry. Its lead product candidates include ABP-100 for the treatment of breast, gastric, and colorectal cancers; and ABP-201 for the treatment of vascular diseases of the eye. The company has a strategic partnership with Abpro Bio Co. Ltd and NJCTTQ. The company was formerly known as Abpro Corporation and changed its name to Abpro Holdings, Inc. in November 2024. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ABPBeat Rate
100%
Last 1 quarters
Avg Surprise
+47.5%
EPS vs Estimate
Beats / Misses
1/0
Last 12 quarters
Latest EPS
$-0.63
Q4 2025
EPS Surprise History
Q3 25
No data
Q4 25
+47.5%
$-0.63vs$-1.20
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 14, 2025 | $-1.20 | $-0.63 | +47.5% | ✓ BEAT |
Q3 2025 | Aug 13, 2025 | — | $-1.20 | — | — |
Latest News
Abpro And Its Co-development Partner Celltrion Submitted An Investigational New Drug Application To FDA For ABP-102/CT-P72 HER2-Positive Cancers
📈 PositiveBenzinga•Dec 15, 2025, 12:12 PM
Abpro Granted Nasdaq Listing Extension As It Cuts Operating Expenses 60% And Secures Up To $44M Flexible Equity Financing To Advance ABP-102 Toward 2026 First-In-Human Trials
📈 PositiveBenzinga•Dec 9, 2025, 12:11 PM
Abpro shares are trading higher after the company announced it will present new preclinical data for CT-P72/ABP-102 at the Society for Immunotherapy of Cancer 2025 Annual Meeting.
📈 PositiveBenzinga•Nov 4, 2025, 02:22 PM
Abpro To Present Data For CT-P72/ABP-102 Tetravalent Bispecific Antibody At Society For Immunotherapy Of Cancer
📈 PositiveBenzinga•Nov 4, 2025, 02:17 PM
Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Nov 3, 2025, 01:55 PM
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Oct 31, 2025, 11:50 PM
Abpro Announces 1-For-30 Reverse Stock Split, Effective October 31, 2025
📉 NegativeBenzinga•Oct 22, 2025, 09:15 PM
Maxim Group Downgrades Abpro Hldgs to Hold
📉 NegativeBenzinga•Oct 21, 2025, 03:01 PM
Abpro Holdings shares are trading lower. The company recently appointed Adam Mostafa as CFO
📉 NegativeBenzinga•Sep 9, 2025, 03:41 PM
Frequently Asked Questions about ABP
What is ABP's current stock price?
Abpro Corporation (ABP) is currently trading at $5.06 per share. The stock has moved +5.64% today.
What is the analyst price target for ABP?
No analyst price targets are currently available for this stock.
What sector is Abpro Corporation in?
Abpro Corporation operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ABP's market cap?
Abpro Corporation has a market capitalization of $0.01 billion, making it a small-cap company.
Does ABP pay dividends?
No, Abpro Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAEON
AEON Biopharma, Inc.
$1.08
Mkt Cap: $0.0B
APM
Aptorum Group Limited
$1.13
Mkt Cap: $0.0B
BOLT
Bolt Biotherapeutics, Inc.
$5.16
Mkt Cap: $0.0B
CING
Cingulate Inc.
$3.97
Mkt Cap: $0.0B
CLRB
Cellectar Biosciences, Inc.
$2.68
Mkt Cap: $0.0B
EVGN
Evogene Ltd.
$1.02
Mkt Cap: $0.0B
LYRA
Lyra Therapeutics, Inc.
$3.60
Mkt Cap: $0.0B
MBIO
Mustang Bio, Inc.
$1.09
Mkt Cap: $0.0B
MRKR
Marker Therapeutics, Inc.
$1.28
Mkt Cap: $0.0B
SNSE
Sensei Biotherapeutics, Inc.
$8.86
Mkt Cap: $0.0B
Explore stocks similar to ABP for comparison